Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.

Comenzo RL, Hassoun H, Kewalramani T, Klimek V, Dhodapkar M, Reich L, Teruya-Feldstein J, Fleisher M, Filippa D, Nimer SD.

Leukemia. 2006 Feb;20(2):345-9.

PMID:
16319952
2.

Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.

Blimark C, Veskovski L, Westin J, Rödjer S, Brune M, Hjorth M, Holmberg E, Andersson PO, Mellqvist UH.

Eur J Haematol. 2011 Aug;87(2):117-22. doi: 10.1111/j.1600-0609.2011.01634.x.

PMID:
21535157
3.

Hematopoietic stem cell transplants for multiple myeloma.

Tricot G, Jagannath S, Vesole DH, Bracy D, Desikan KR, Siegel D, Barlogie B.

Leuk Lymphoma. 1996 Jun;22(1-2):25-36. Review.

PMID:
8724525
4.

Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?

Seyfarth B, Kuse R, Sonnen R, Glass B, Schmitz N, Dreger P.

Ann Hematol. 2001 Jul;80(7):398-405.

PMID:
11529465
5.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ; Medical Research Council Adult Leukaemia Working Party.

N Engl J Med. 2003 May 8;348(19):1875-83.

6.

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Long GD, Horwitz ME, Keogh G, Chute JP, Sullivan KM, Neuwirth R, Davis PH, Sutton LM, Anderson RD, Chao NJ, Rizzieri D.

Biol Blood Marrow Transplant. 2010 Jan;16(1):70-7. doi: 10.1016/j.bbmt.2009.08.017. Epub 2009 Sep 3.

7.

Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.

Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D, Alexanian R, Giralt S.

Cancer. 2004 Jun 15;100(12):2607-12.

8.

High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.

Ager S, Mahendra P, Richards EM, Bass G, Baglin TP, Marcus RE.

Bone Marrow Transplant. 1996 Mar;17(3):335-40.

PMID:
8704683
9.

Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma.

Weaver CH, Zhen B, Schwartzberg LS, Leff R, Magee M, Geier L, Deaton K, Lewkow L, Buckner CD.

Bone Marrow Transplant. 1998 Aug;22(3):245-51.

10.

Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.

Palumbo A, Avonto I, Bruno B, Ambrosini MT, Bringhen S, Cavallo F, Falco P, Boccadoro M.

Eur J Haematol. 2006 Apr;76(4):273-7.

PMID:
16519697
11.

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, Swift R.

J Clin Oncol. 2006 Feb 20;24(6):937-44. Epub 2006 Jan 17.

PMID:
16418495
12.

Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.

Novitzky N, Thomson J, Thomas V, du Toit C, Mohamed Z, McDonald A.

Biol Blood Marrow Transplant. 2010 Oct;16(10):1402-10. doi: 10.1016/j.bbmt.2010.04.002. Epub 2010 Apr 10.

13.

[Comparison of regimen-related toxicity between high-dose melphalan and ICE as a preparatory regimen for autologous stem cell transplantation].

Imataki O, Aoyama T, Tamai Y, Kawakami K.

Gan To Kagaku Ryoho. 2007 Oct;34(10):1633-6. Japanese.

PMID:
17940379
14.

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC.

J Clin Oncol. 2006 Feb 20;24(6):929-36. Epub 2006 Jan 23. Erratum in: J Clin Oncol. 2006 Jun 10;24(17):2687. Moore, Dennis F Jr [added].

PMID:
16432076
15.

High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.

Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, Sharma A, Singh R, Kochupillai V.

Natl Med J India. 2003 Jan-Feb;16(1):16-21.

PMID:
12715951
16.
17.

Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.

Tosi P, Zamagni E, Ronconi S, Benni M, Motta MR, Rizzi S, Tura S, Cavo M.

Leukemia. 2000 Jul;14(7):1310-3.

PMID:
10914557
18.

Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.

Martino M, Postorino M, Gallo GA, Messina G, Neri S, Piro E, Gentile M, Moscato T, Monteleone R, Fedele R, Mazzone C, Console G, Penna G, Alati C, Vincelli ID, Irrera G, Musolino C, Ronco F, Molica S, Morabito F.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):148-54. doi: 10.1016/j.clml.2013.11.009. Epub 2013 Nov 22.

PMID:
24417912
19.

Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.

Fenk R, Liese V, Neubauer F, Bruns I, Kondakci M, Balleisen S, Saure C, Schröder T, Haas R, Kobbe G.

Leuk Lymphoma. 2011 Aug;52(8):1455-62. doi: 10.3109/10428194.2011.575967. Epub 2011 Jun 10.

PMID:
21657961

Supplemental Content

Support Center